In the linagliptin CARMELINA trial, 6991 patients with type 2 diabetes and at high CVD and renal risk were randomly assigned to linagliptin or placebo, in addition to other diabetes medications (predominantly metformin, sulfonylurea and insulin) [84]. Here, INS is linked to diabetes mellitus.